Harbour BioMed Completes China Phase II Trial of Dry Eye Treatment

Harbour BioMed
Published on: October 11, 2019
Author: Amy Liu

Harbour BioMed (HBM) completed a China Phase II trial of HBM9036 (tanfanercept), a novel TNF receptor-1 fragment indicated for moderate-to-severe Dry-Eye-Disease. In 2017, Harbour in-licensed China rights to the candidate in a two-drug deal from Korea’s HanAll, which also included a treatment for pathogenic IgG-mediated autoimmune diseases. Harbour pointed out that OTC dry eye drops alleviate the symptoms of DED, but do not address the underlying inflammation. Harbour is headquartered in Boston, with operations in the Netherlands and Shanghai.

Source: China Biotoday

Biotechnology Healthcare Services Life Science Pharmaceutical